Susceptibility to myasthenia gravis (MG) is positively linked to expression of HLA-DQ8 and DR3 molecules and negatively linked to expression of the DQ6 molecule. To elucidate the molecular basis of this association, we have induced experimental autoimmune MG (EAMG) in mice transgenic for HLA-DQ8, DQ6, and DR3, and in DQ8×DQ6 and DQ8×DR3 F 1 transgenic mice, by immunization with human acetylcholine receptor (H-AChR) in CFA. Mice expressing transgenes for one or both of the HLA class II molecules positively associated with MG (DQ8 and DR3) developed EAMG. T cells from DQ8 transgenic mice responded well to three cytoplasmic peptide sequences of H-AChR (a320-337, a304-322, and a419-437), of which the response to a320-337 was the most intense. DR3 transgenic mice also responded to this sequence very strongly. H-AChR-and a320-337 peptidespecific lymphocyte responses were restricted by HLA class II molecules. Disease resistance in DQ6 transgenic mice was associated with reduced synthesis of anti-AChR IgG, IgG 2b , and IgG 2c Ab's and reduced IL-2 and IFN-g secretion by H-AChR-and peptide a320-337-specific lymphocytes. Finally, we show that DQ8 imparts susceptibility to EAMG and responsiveness to an epitope within the sequence a320-337 as a dominant trait.
Introduction
sequence (16) (17) (18) (19) . Neonatal tolerance to T-α146-162 peptide, and nasal or systemic administration to adult C57BL/6 mice of synthetic peptides within the sequence T-α146-169, prevented EAMG development after T-AChR immunization (19) (20) (21) (22) . When using systemic high doses of a T-α146-162 peptide, the resulting tolerance was mediated by the Fas/Fas ligand pathway, apoptosis, and clonal anergy of AChR-reactive CD4 + cells (23) . Unlike T cells from wild-type C57BL/6 mice, those from HLA-DQ8 and HLA-DR3 transgenic mice immunized with T-AChR recognized, primarily, two promiscuous determinants within residues 141-160 and 170-190 of the human AChR (H-AChR) α subunit (15) .
In this study, we induced EAMG by H-AChR immunization and characterized the H-AChR T cell epitopes involved in activation of T cells, and the cytokines secreted by the anti-H-AChR T cells. Toward that goal, we immunized HLA transgenic mice with H-AChR derived from the human muscle-like TE671 cell line. H-AChR-immunized HLA-DQ8, DR3, DQ8×DR3 F 1 , and DQ8×DQ6 F 1 mice developed clinical EAMG, whereas HLA-DQ6 mice were less susceptible. The cytoplasmic H-AChR peptide α320-337 (H-α320-337) was the dominant T cell epitope for DQ8, DR3, and DQ8×DQ6 F 1 mice. The HLA class II-restricted lymphocyte response against H-AChR and peptide H-α320-337 and susceptibility to EAMG were inherited as a dominant trait in DQ8×DQ6 F 1 mice.
Methods
Mice. We used transgenic mice deficient in the mouse MHC class II molecules, which bear only a human HLA-DQ (Aβ 0 .DQ8 or Aβ 0 .DQ6) or DR (Aβ 0 .DR3) molecule. The mice express functional HLA-DQ8 (HLA-DQA1*0301/DQB1*0302), DQ6 (HLA-DQA1*0103/ DQB1*0601), or DR3 (HLA-DRA1*0101/DRB1*0301) genes in the C57BL/10 background. All of the transgenic mice, except DQ8×DQ6 F 1 mice, were obtained after the tenth backcross generation to C57BL/10 mice. The Aβ 0 .DR3 (DR3) mice were mated with Aβ 0 .DQ8 (DQ8) mice to obtain the DQ8×DR3 F 1 mice. The fourth backcross generation of Aβ 0 .DQ8 and Aβ 0 .DQ6 (DQ6) mice were mated to derive DQ8×DQ6 F 1 mice. In all of the transgenic mice, expression of HLA class II and absence of endogenous MHC class II molecules were verified by FACS and PCR (14, 15, 24, 25) . The percentage of CD4 + and CD8 + cells in the peripheral blood leukocytes of transgenic mice before immunization was analyzed by flow cytometry as previously demonstrated (25) . CD4 + cells in the different strains were: DQ6, 15.68% ± 3.55%; DQ8, 14.02% ± 2.20%; DR3, 15.73% ± 3.03%; and DQ8×DR3 F 1 , 16.08% ± 4.41%; while CD8 + cells were as follows: DQ6, 10.14% ± 1.12%; DQ8, 11.42% ± 2.76%; DR3, 11.34% ± 4.89%; and DQ8×DR3 F 1 , 10.6% ± 1.60%. No significant differences between these strains of mice were found. Therefore, the immune system in HLA transgenic mice developed normally, with appropriate expression and functionality of MHC class II molecules. All transgenic lines were initially bred at the Mayo Clinic and then bred and housed in the viral Ab-free barrier facility at the University of Texas Medical Branch. All experiments were performed according to the Animal Care and Use Committee guidelines.
Purification of human AChR, biological activity, and SDS-PAGE. H-AChR was purified from the TE671 cell line (American Type Culture Collection, Rockville, Maryland, USA), which expresses H-AChR, by an α-neurotoxin affinity column. The TE671 cell line was cultured in 150-cm 2 cell culture flasks at 37°C in Dulbecco's modification of Eagle's medium supplemented with 2 mM/l L-glutamine, and 10% of FBS in the presence of 100 U/ml penicillin G and 100 µg/ml streptomycin. Confluent cells were harvested every 3-4 days. Cells were washed in homogenization buffer containing 5 mM/l Tris (pH 7.8), 10 mM/l EDTA, 10 mM/l EGTA, 0.1 g/l phenylmethylsulfonyl fluoride, and 0.2 g/l sodium azide. The cells were removed from the flask, and cells collected from 70-100 flasks were used for one affinity purification procedure. After washing, the pellet was resuspended in a small amount of homogenizing buffer, and 0.1 vol of 10% Triton (1% Triton X-100) was added to the TE671 cells and agitated for 4 hours on a shaker at low speed at 4°C. The extract was centrifuged for 30 minutes at 100,000 g at 4°C. AChR containing supernatant was added to neurotoxin 3-agarose (Sigma Chemical Co., St. Louis, Missouri, USA) in a glass flask and agitated gently in a shaker for 4 hours at 4°C. The next day, AChR extract/neurotoxin 3-agarose mixture was poured into a 1.5 × 20-cm Econo column (Bio-Rad Laboratories, Life Science Group, Hercules, California, USA). The mixture was poured down the sides of the column and the buffer allowed to run out of the column. After beads were packed, supernatants were allowed to run out of the column until a small amount covered the top. NaCl/Triton buffer was added to the top, and the column was washed with 100 ml of buffer. Following this step, both the toxin affinity and hydroxylapatite columns were washed with 300 ml 0.2% cholate buffer. Buffer from the top of both columns was removed, and 1 M carbamylcholine buffer (26) (Sigma Chemical Co.) was added. Then the hydroxylapatite column, but not the neurotoxin 3 column, was washed with 100 ml of 1 M carbamylcholine buffer. Plastic tubing from both the columns was connected to a pump. The peristaltic pump was run at a rate of 50 ml/h, and the mixture was allowed to circulate for 14-16 hours. The connection between the toxin affinity and the hydroxylapatite columns was removed, and H-AChR was eluted with 152 mM phosphate elution buffer (26) into a fraction collector. The total yield from each purification varied with an average of 5 mg pure H-AChR protein from 40 to 60 g TE671 cells. We evaluated the ability of the H-AChR preparations to bind specifically to [ 125 I]α-bungarotoxin ([ 125 I]α-BTX). One microgram of affinity-purified H-AChR had 92-219 nM of α-BTX-binding sites. SDS-PAGE confirmed the purity of fetal H-AChR preparations with appropriate molecular weight of α (in duplicate), β, γ, and δ subunits ( Figure 1 ) (27) .
Peptides. The peptides used in this study were synthesized by parallel synthesis (28) . Most of them were 14-20 residues long and overlapped by three to five residues. They spanned most of the H-AChR α subunit sequence. Their position in the AChR α subunit and their sequences are reported in Table 1 . The synthesis and characterization of these peptides have been reported (29) (30) (31) (32) (33) . They were successfully used to identify the epitope repertoire of CD4 + cells from MG patients (29) (30) (31) (32) (33) lymph node cells (LNCs) at 4 × 10 5 cells in 200 µl were exposed in triplicate to each of the H-AChR-α (H-α) subunit peptides (40 µg/ml) and H-AChR (0.5 µg/ml). Inguinal, paraortic, and axillary LNCs of individual mice derived on day 90 of the long-term experiment were cultured in triplicate with H-α320-337 peptide (40 µg/ml) or H-AChR (0.5 µg/ml). The culture medium contained RPMI-1640, supplemented with 10% FCS, penicillin G (100 U/ml) streptomycin (100 µg/ml), L-glutamine (2 mM), 2-mercaptoethanol (3 × 10 -5 M), and HEPES buffer (25 mM). The cells were cultured for 5 days at 37°C in humidified 5% CO 2 -enriched air, and pulse-labeled with [ 3 H]TdR (1 µCi per well) for 18-20 hours before harvesting. The 3 H incorporation was determined in a Beckman beta scintillation counter (Beckman Coulter Inc., Fullerton, California, USA). The results are expressed as ∆cpm (cpm with antigen minus cpm with media).
Anti-DQ and -DR Ab inhibition studies. DR3 and DQ8 mice (four of each) were immunized with H-AChR (20 µg per mice) in CFA. A week later, the mice were euthanized, and the pooled draining popliteal and inguinal LNCs in triplicate wells were cultured for 5 days with H-AChR (0.5 µg/ml), with or without mAb's specific for HLA-DQ (Leinco Technologies Inc., St. Louis, Missouri, USA; clone 1a3) or HLA-DR molecules (PharMingen, San Diego, California, USA; clone G46-6, dialyzed to remove sodium azide). The extent of cell proliferation was determined from the incorporation of 3 H-thymidine. After overnight incubation at 4°C, goat anti-mouse IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, Pennsylvania, USA) was added to 1 ml of [ 125 I]α-BTX-labeled AChR. After 4 hours, the tubes were centrifuged, and the pellets were washed with 1 ml of Triton buffer, centrifuged again, and counted in a gamma counter. The AChR precipitated, minus the control value, gave the serum Ab amounts in nanomoles (nM) of α-BTX-binding sites bound per liter of serum.
ELISA of anti-M-AChR Ig isotype. Affinity-purified M-AChR (0.5 µg/ml) was coated onto a 96-well microtiter plate in 0.1 M carbonate bicarbonate buffer (pH 9.6) overnight at 4°C. The plates were blocked with 2% BSA in PBS at room temperature for 30 minutes. Diluted serum samples of 100 µl (IgG, IgG 1 , IgG 2b , and IgG 2c 1:2500; IgM 1:100) were added and incubated at 37°C for 90 minutes. After four washes, horseradish peroxidase-conjugated anti-mouse IgM, IgG, IgG 1 , and IgG 2b (Caltag Laboratories, Burlingame, California, USA) and anti-mouse IgG 2c (PharMingen), diluted 1:1000 in PBS 0.05% Tween-20, were added and incubated at 37°C for 90 minutes. Subsequently, 0.3 mg/ml of diammonium 2,2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonate) substrate (ABTS) solution was added to the IgM, IgG, IgG 1 , and IgG 2b plates and 100 µl of avidin-labeled peroxidase (Sigma Chemical Co.) at 2.5 µg/ml was added to the IgG 2c plate and incubated for 30 minutes. Subsequently, the peroxidase indicator substrate ABTS, in 0.1 M citric buffer, pH 4.35, was added in the presence of H 2 O 2 , and the mixture was allowed to develop color at room temperature in the dark. Plates were read at a wavelength of 405 nm. Serially diluted anti-AChR sera were used as a positive control, and normal mouse serum (collected from mice before H-AChR immunization) was used for background determination. The results are expressed as ∆OD (OD from sera after AChR immunization minus OD from sera before AChR immunization).
Radioimmunoassay of M-AChR content. 0.1-ml aliquots of [ 125 I]α-BTX-labeled (5 × 10 -9 M), Triton X-100-solubilized mouse muscle extract, both with and without benzoquinonium (10 -3 M), were mixed with 10 µl of antiAChR serum. The resulting complex was precipitated by goat anti-mouse serum and then sedimented by centrifugation, washed in 1 ml of Triton buffer, and sedimented again. Radioactivity of the pellet was counted in a Packard gamma counter (Packard Instrument Co., Meriden, Connecticut, USA), and cpm with benzoquinonium was subtracted from cpm of experimental samples without benzoquinonium. The concentration of AChR was expressed as pM of [ 125 I]α-BTX-binding sites per gram of mouse carcass.
ELISA of cytokines secreted by cultured LNCs. At the end of the long-term experiment, draining LNCs (inguinal, paraaortic, and axillary) from individual mice were cultured in 48-well, flat-bottomed plates in the presence of H-AChR (0.5 µg /ml) or H-α320-337 peptide (40 µg/ml); and at 48, 72, or 96 hours, the supernatant was collected for IL-2, IL-10, and IFN-γ measurement. Wells in ELISA plates (Immunol 2; Dynatech Laboratories, Chantilly, Virginia, USA) were coated with 2 µg/ml (50 µl per well) of one of the anti-cytokine (IL-2, IFN-γ, and IL-10; PharMingen) mAb's in 0.1 M carbonate buffer, pH 8.2
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The overnight at 4°C. The plates were blocked with 200 µl of 10% FCS in PBS for 2 hours. Supernatant sample (100 µl) and various dilutions of cytokine standards (PharMingen) were added, titered to the linear portion of the absorbance/concentration curve in duplicate, and incubated overnight at 4°C. After the plates were washed six times with PBS and Tween-20 (0.05%), 100 µl biotinylated anti-cytokine mAb (with different epitopic determinants than the Ab used to coat ELISA plates) at 1 µg/ml in PBS containing 10% FCS were added for 45 minutes at room temperature. After vigorous washing, 100 µl of avidin-labeled peroxidase (Sigma Chemical Co.) at 2.5 µg/ml was added and incubated for 30 minutes. Subsequently, the peroxidase indicator substrate ABTS in 0.1 M citric buffer, pH 4.35, was added in the presence of H 2 O 2 , and the OD was measured at 405 nm using the ELISA reader from Molecular Devices Corp.
(Sunnyvale, California, USA). The negative (background) controls were culture medium. The concentration of specific cytokine samples was measured based on cytokine standards (IFN-γ and IL-10, PharMingen; IL-2, R&D Systems Inc., Minneapolis, Minnesota, USA).
Results

H-AChR immunization induced clinical EAMG in DQ8
, DR3, DQ8×DR3 F 1 , and DQ8×DQ6 F 1 mice. DQ6 mice were relatively resistant to clinical EAMG when immunized with T-AChR (14) . In our study, before the second AChR immunization, two of eight DR3 mice (25%) and one of eight DQ8 mice (12.5%) developed grade 1 EAMG. After the second immunization, five of eight DQ8 (62.5%) and four of eight DR3 mice (50%) developed grade 1 or 2 EAMG. The accumulated total clinical incidence at the end of the experiment was six of eight (75%) for DQ8 and DR3 mice. The time course of the accumulated incidence of clinical EAMG and the time of onset of the clinical disease are illustrated in Figure 2a and the time course of the clinical score (mean grade) is illustrated in Figure 2b . Only two of eight DQ6 mice (25%) developed low-grade, clinical EAMG after the third immunization. Therefore, DQ6 mice are relatively resistant to EAMG and develop less severe disease when immunized with either H-AChR (this study) or T-AChR (14) . Since both DQ8 and DR3 alleles are positively associated with MG, we examined the susceptibility to EAMG of DQ8×DR3 F 1 mice, which express both the DQ8 and the DQ3 molecules. Eight of ten DQ8×DR3 F 1 mice (80%) developed clinical EAMG, and one died at 44 days after the second immunization because of severe disease (Figure 2, a and b) . Expression of I-Eα K β b (I-E) molecule (equivalent to human DR molecule) in B10 mice suppressed EAMG development (34) . However, in HLA transgenic mice, expression of the DR3 molecule in the presence of EAMG susceptible DQ8 molecule did not suppress clinical EAMG.
Next we examined whether simultaneous inheritance of the EAMG-susceptible DQ8 allele and the EAMGresistant DQ6 allele leads to dominant susceptibility to EAMG. DQ8×DQ6 F 1 mice developed clinical EAMG with an incidence and severity similar to those of DQ8 mice ( Figure 2, c and d) , suggesting the dominance of the DQ8 gene in determining EAMG susceptibility. Consistent with the clinical findings, the AChR content of mouse muscle, determined as α-BTX-binding sites, was significantly lower in H-AChR-immunized DQ8, DR3, and DQ8×DR3 F 1 mice than in the resistant DQ6 mice (Figure 3) .
Reduced serum anti-AChR Ab level in DQ6 mice, compared with DQ8, DR3, and DQ8×DR3 F 1 mice. Serum collected on days 15, 45, and 75, after the beginning of the H-AChR immunization, were evaluated for anti-MAChR Ab concentration by an α-BTX radioimmunoassay. The anti-AChR Ab response of all the transgenic strains was low on day 15 after priming with H-AChR, and no differences were observed between transgenic
Figure 3
Muscle AChR content in AChR-immunized transgenic mice. Individual mouse carcasses were extracted to measure muscle AChR (α-BTX-binding sites) by radioimmunoassay and expressed as pM α-BTX-binding sites per gram of mouse carcass. DQ6 mice had increased amounts of functional muscle AChR compared with DQ8, DR3, and DQ8×DR3 F 1 mice. *P < 0.01, Student's t test. There was no difference in the muscle AChR content between normal DQ8 (1.16 ± 0.10 pM/g), DQ6 (0.94 ± 0.07 pM/g), and DR3 (1.25 ± 0.08 pM/g) mice.
Figure 4
Reduced anti-AChR IgG response in DQ6 mice compared with DQ8, DR3, and DQ8×DR3 F 1 mice. Serum individually derived from DQ6, DQ8, DR3, and DQ8×DR3 F 1 mice (eight mice of each group) on days 15, 45, and 75 after the first H-AChR immunization was measured for anti-mouse muscle AChR IgG level by α-BTX radioimmunoassay. The mean value of cpm of prebleeding serum from all transgenic mice was similar (DQ8, 396 ± 55; DR3, 414 ± 47; DQ6, 390 ± 30; DQ8×DR3 F 1 , 400 ± 47). The error bars are SE. *P < 0.01 and **P < 0.05, Student's t test. mice ( Figure 4) . However, at 45 days (15 days after the first H-AChR boost) and at 75 days (15 days after second boost), DQ8, DR3, and DQ8×DR3 F 1 mice had significantly higher concentrations of serum anti-MAChR Ab than did DQ6 mice (Figure 4) . Therefore, the resistance of DQ6 mice to development of clinical EAMG could be due to the reduced production of cross-reactive Ab to mouse muscle AChR.
Reduced serum concentrations of anti-AChR IgG, IgG 1 , IgG 2b , and IgG 2c in DQ6 mice compared with DQ8, DR3, and DQ8×DR3 F 1 mice. Next we examined whether the concentration in the serum of anti-AChR IgG isotypes correlated with development of EAMG in the EAMG-susceptible DQ8, DR3, and DQ8×DR3 F 1 mice, and in the relatively resistant DQ6 mice. Fifteen days after priming with H-AChR, we did not observe significant differences in the primary anti-AChR IgM Ab between DQ6 mice, and DQ8, DR3, and DQ8×DR3 F 1 mice ( Figure 5) . However, the concentration of serum antiAChR IgM Ab level was very low in all of the transgenic mice at that time. On day 75 (after two booster doses of H-AChR), DQ8, DR3, and DQ8×DR3 F 1 mice had significantly higher serum anti-AChR IgM responses than did DQ6 mice ( Figure 5 ). As observed for the α-BTX radioimmunoassay of anti-AChR Ab, also in the ELISA, the serum anti-AChR IgG Ab response was reduced in the DQ6 mice as compared with the DQ8, DR3, and DQ8×DR3 F 1 mice ( Figure 5 ). On days 45 and 75 (after one and two boosts with H-AChR, respectively), DQ6 mice had significantly reduced serum concentrations of anti-AChR IgG 1 , IgG 2b , and IgG 2c isotypes. Therefore, the relative resistance of EAMG in DQ6 mice was associated with reduced secondary response involving anti-AChR IgG 1 , IgG 2b , and IgG 2c Ab isotypes.
The sequence α320-337 of the H-AChR forms a dominant T cell epitope for DQ8, DR3
, and DQ8×DQ6 F 1 mice. We next mapped the T cell epitopes on the H-AChR α subunit by challenging LNCs from H-AChR-immunized DQ8, DR3, DQ6, and DQ8×DQ6 F 1 mice, with overlapping synthetic peptides spanning most of the sequence of the H-AChR α subunit. Peptide α320-337 was most strongly recognized by T cells of H-AChR-immunized DQ8, DR3, and DQ8×DQ6 F 1 mice ( Figure 6 ). Peptide α304-322 was a subdominant epitope in DQ8 mice. H-AChR-immunized T cells of DR3 mice responded well (>40,000 cpm) to numerous peptides of the H-AChR α subunit (α320-337, α376-393, α304-322, α261-280, α89-105, and α76-93). H-AChR-immune DQ6 mouse T cells responded moderately (∼20,000 cpm) to peptide α304-322 and did not respond to any other H-AChR α subunit peptides. H-AChR-immune T cells from DQ8×DQ6 F 1 mice responded to almost all of the peptides recognized by H-AChR-immune T cells from DQ8 mice.
Reduced AChR-specific lymphocyte proliferation and production of IFN-γ and IL-2 in DQ6 mice as compared with DQ8, DR3, and DQ8×DQ6 F 1 mice. Ninety days after the first H-AChR immunization, LNCs from all the transgenic mice were cultured in vitro with H-AChR or peptide H-α320-337, and examined for lymphocyte proliferation and cytokine secretion. H-AChR-and H-α320-337-specific proliferation was significantly lower for LNCs from DQ6 mice than for those from DQ8, DR3, and DQ8×DQ6 F 1 mice (Figure 7a ). We measured IL-2, IL-10, and IFN-γ in supernatants collected after 48, 72, and 96 hours of culture, respectively. H-AChR-and H-α320-337-specific IFN-γ and IL-2
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The production was significantly higher in cultures of LNCs from DR3, DQ8, and DQ8×DQ6 F 1 mice than in those of LNCs from DQ6 mice ( Figure 7 , b and c).
There were no significant differences in IL-10 responses between different transgenic mice (Figure 7d ). 
H-AChR-and H-α320-337 peptide-specific lymphocyte responses in DQ8 and
Discussion
Although numerous studies have examined the association of HLA class II gene polymorphism with susceptibility to MG or other autoimmune diseases, the molecular mechanisms by which HLA class II genes influence the development of autoimmune diseases are still obscure. This is because the HLA system is very complex, and the presence of gene clusters and of linkage disequilibrium further complicates this issue. HLA transgenic mice were generated in an attempt to reduce this complexity in a biologically relevant setting. The HLA transgenic mice we used do not express endogenous class II molecules: thus, the only MHC class II gene products involved in antigen presentation in these mice are the human DQ8, DR3, or DQ6 molecules. These HLA class II transgenic mice expressed normal levels of CD4 + and CD8 + cells (25) , confirming that the transgenic HLA class II molecules can interact with the mouse CD4 molecule and T cell receptors.
Previous studies used panels of overlapping synthetic peptides spanning the sequence of the different H-AChR subunits, to examine the CD4 + T cell response of PBMCs from MG patients, or H-AChR-specific CD4 + T cell lines derived from MG patients, to identify H-AChR T cell epitopes (29) (30) (31) (32) (33) (35) (36) (37) (38) (39) (40) (41) (42) (43) . Those studies identified a number of sequence regions recognized by CD4 + cells of MG patients, including a few immunodominant epitopes, which were recognized by the majority of MG patients on each human AChR subunit; several of those epitopes were within the H-AChR α subunit. Harcourt et al. reported that peptide 257-269 from H-AChR stimulated cells from six patients and no controls (42) . However, MHC class II restriction of this peptide-induced lymphocyte response was not studied. Other studies (44, 45) demonstrated that the AChR sequence regions immunodominant for sensitization of CD4 + cells in MG patients could associate with a variety of purified DR
Figure 6
T cell epitope mapping on the H-AChR α subunit in DQ6, DQ8, DR3, and DQ8×DQ6 F 1 transgenic mice immunized with H-AChR. The transgenic mice were immunized in the footpad with H-AChR (20 µg) in CFA. Seven days later, draining LNCs (popliteal and inguinal) were exposed to each of the overlapping synthetic H-AChR α subunit peptides (40 µg/ml) and H-AChR (0.5 µg/ml), and 3 H incorporation was determined. The error bars are SE.
molecules. Those studies demonstrated that the sequence α320-337 was recognized by several MG patients (31, 44, 45) , and that this sequence could bind effectively to three of the four DR molecules tested (DR2, DR4, and DR7) (44) . T cell lines were generated against the full-length recombinant H-AChR α subunit (41); peptides 75-115 and 138-167 were restricted by DR4, and peptide 309-344 was restricted by DR3 or DR52a (41) . However, those studies did not examine the association of any particular dominant H-AChR T cell epitopes with a particular HLA-DQ molecule.
In our current study, we used HLA-DQ8 and DR3 transgenic mice to identify the dominant H-AChR-α subunit T cell epitopes recognized by T cells during the The sequence H-α320-337, which is part of the cytoplasmic domain of the H-AChR, might form a promiscuous epitope (44) , recognized by T cells of MG patients with different HLA-DQ or DR alleles, beside the DQ8 and DR3 alleles. The finding that this peptide
Figure 7
Reduced H-AChR-and α320-337 peptide-specific lymphocyte proliferative response and IFN-γ and IL-2 secretion in DQ6 mice compared with DQ8, DR3, and DQ8×DR3 F 1 mice. At termination of the long-term experiment (day 90), LNCs from DQ6, DQ8, DR3, and DQ8×DR3 F 1 mice were cultured in vitro with H-AChR (0.5 µg/ml), peptide α320-337 (40 µg /ml), and PBS, and supernatants collected after 48, 72, and 96 hours were used for IL-2, IL-10, and IFN-γ measurement, respectively. Because of the reduced number of cells, the LNCs from two mice in one group were pooled. For the lymphocyte proliferation, total samples were six DQ6 mice and eight each of DQ8, DR3, and DQ8×DR3 F 1 mice; for the supernatant cytokine test, total samples were three DQ6, seven DQ8, five DR3, and five DQ8×DR3 
Figure 8
Effect of anti-DR or -DQ Ab on in vitro AChR-and α320-337 peptide-specific lymphocyte proliferation response. Pooled LNCs from four H-AChR-immunized DQ8 mice and four H-AChR-immunized DR3 mice were cultured in vitro with H-AChR (0.5 µg/ml) or H-α320-337 peptide (40 µg/ml), and anti-HLA-DQ or anti-HLA-DR mAb (2.5 µg/ml). *P < 0.05, Student's t test.
is frequently recognized by CD4 + cells of MG patients, irrespective of their class II haplotype (30, 31) , supports this possibility. Identification of one dominant epitope H-α320-337 for two HLA alleles (DQ8 and DR3) closely linked to MG susceptibility goes beyond the primary mapping of H-AChR T cell epitope in MG patients. Epitopes within this sequence could sensitize CD4 + T cells during the initial priming with H-AChR or with a cross-reactive antigen (i.e., microbial antigen). It is also possible that when the mouse neuromuscular junction AChR is destroyed by Ab binding and complementmediated lysis, AChR fragments could be processed, and dominant epitope(s) (including α320-337) could be presented to T cells and maintain the autoimmune T cell response to the AChR.
The relative resistance to clinical EAMG of DQ6 mice after immunization with H-AChR and the negative association of the DQ6 allele with human MG could imply that the DQ6 molecule is less efficient in binding and/or presentation of dominant pathogenic T cell epitopes of the H-AChR. It is also possible that individuals bearing the DQ6 allele have reduced T cells potentially reactive to AChR T epitopes. MHC class II molecules influence the peptide-binding characteristics during immune response. HLA-DQ8 and DR3 bind few or more autoantigenic peptides that contribute to MG development, and the DQ6 molecule either does not bind these autoantigenic peptides, or else binds them in an altered binding motif such that different residues could be presented to the T cell receptor.
There was no difference in the anti-AChR IgM Ab response in H-AChR-immunized DQ8, DR3, and F 1 mice (all susceptible to EAMG), and the EAMG-resistant DQ6 mice. However, all the serum anti-AChR IgG isotypes we tested (IgG 1 , IgG 2b , and IgG 2c ) were lower in DQ6 mice than in DQ8, DR3, and F 1 mice. This suggests that the B cells of DQ6 mice have antigen receptors specific for mouse AChR in normal numbers, but less capable of mounting a secondary Ab response to the mouse AChR. The overall T cell response to the H-AChR α subunit epitopes leads to a strong production of cytokines (i.e., IL-2 and IFN-γ), which may activate H-AChR-specific B cells in DQ8 and DR3 mice. The defect in switching from antiAChR IgM to IgG could be due to the reduced T cell responses, and the reduced IFN-γ and IL-2 production that we observed in DQ6 mice after immunization with H-AChR. Also, the resistance of HLA-DQ6 mice to EAMG induced by immunization with T-AChR was associated with a reduced AChR-specific production of IFN-γ, IL-2, and IL-10 (46). It is of interest that H-AChR-immune T cells of both DQ8 and DR3 mice, which are susceptible to EAMG, responded dominantly to the H-α320-337 peptide. Also, the H-α320-337 peptide response was dominant in DQ8×DQ6 F 1 mice. The I-A b gene was codominant for clinical EAMG susceptibility when mice were immunized with T-AChR (47). Thus, one MG-susceptible HLA-DQ allele in a heterozygote could be sufficient for full expression of MG.
We report several new findings in this paper: (a) H-AChR derived from TE671 muscle-like cell line has been purified by neurotoxin affinity chromatography. The EAMG resistance of DQ6 mice was associated with a reduced H-AChR-specific production of IFN-γ and IL-2. (f) We have characterized the dominant human class II-restricted H-AChR α subunit T cell epitope H-α320-337 for DQ8 and DR3 transgenic mice.
EAMG can be prevented or suppressed in T-AChRprimed I-A b mice by injection of high doses of T-α146-162 peptide in incomplete Freund's adjuvant or by nasal or subcutaneous treatment with solutions of the peptide T-α150-169 (20) (21) (22) (23) . The H-AChR peptide α320-337, identified here as immunodominant in DR3 and DQ8 transgenic mice, might be used for similar therapeutic tolerance approaches in MG patients.
